A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Part of paid clinical trials in Tampa, Florida.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT04104776
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tulmimetostat — DRUG
    Tulmimetostat dosed once per day orally in 28 day cycles
  • Enzalutamide — DRUG
    Enzalutamide dosed once per day orally in 28 day cycles

Study Details

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.

Key Dates

Start date
Sep 18, 2019
Status verified
Jun 2026
Primary completion
Feb 27, 2030
Completion
Feb 27, 2030

Study Design

Enrollment
275 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1
    Eligible participants with advanced tumors will receive escalating doses of Tulmimetostat once per day orally.
  • Experimental: Phase 2 - Cohort M1 (Advanced/metastatic solid tumors or urothelial carcinoma with ARID1A mutation)
    Eligible participants with advanced/metastatic solid tumors (excluding ovarian clear cell and endometrial carcinoma) or urothelial carcinoma, confirmed to have ARID1A mutations will receive oral Tulmimetostat once daily in 28-day treatment cycles.
  • Experimental: Phase 2 - Cohort M2 (Ovarian clear cell carcinoma with ARID1A mutation)
    Eligible participants with advanced ovarian clear cell carcinoma, confirmed to have ARID1A mutations, who have received prior platinum-based chemotherapy will receive oral Tulmimetostat once daily in 28-day treatment cycles.
  • Experimental: Phase 2 - Cohort M3 (Endometrial carcinoma with ARID1A mutation)
    Eligible participants with recurrent, metastatic, or unresectable endometrial carcinoma, confirmed to have ARID1A mutations, and prior platinum-based therapy will receive oral Tulmimetostat once daily in 28-day treatment cycles.
  • Experimental: Phase 2 - Cohort M4 (Relapsed/refractory lymphoma (PTCL or DLBCL))
    Eligible participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) or diffuse large B-cell lymphoma (DLBCL), including those with EZH2 hotspot mutations will receive oral Tulmimetostat once daily in 28-day treatment cycles.
  • Experimental: Phase 2 - Cohort M5 (Malignant mesothelioma with BAP1 loss)
    Eligible participants with relapsed or refractory malignant pleural or peritoneal mesothelioma, confirmed to have BAP1 loss will receive oral Tulmimetostat once daily in 28-day treatment cycles.
  • Experimental: Phase 2 - Cohort M6 (Metastatic castration-resistant prostate cancer (mCRPC))
    Eligible participants with mCRPC, measurable soft tissue disease, and prior treatment with at least one androgen receptor signaling inhibitor and one taxane-based chemotherapy will receive oral Tulmimetostat once daily in 28-day treatment cycles.
  • Experimental: Phase 2 - Cohort M7 (Food effect in ARID1A wildtype endometrial carcinoma)
    Eligible participants with recurrent, advanced endometrial carcinoma that is ARID1A wildtype (no ARID1A mutation), to evaluate the effect of food on DZR123 pharmacokinetics will receive oral Tulmimetostat once daily in 28-day treatment cycles.
  • Experimental: Cohort M8 - Part 1 (Tulmimetostat + enzalutamide in mCRPC)
    Eligible participants with mCRPC receive DZR123 in combination with enzalutamide. Part 1 is dose escalation to determine the recommended dose.
  • Experimental: Cohort M8 - Part 2 (Tulmimetostat + enzalutamide in mCRPC)
    Eligible participants with mCRPC receive DZR123 in combination with enzalutamide. Part 2 is expansion at the selected dose to further assess safety and antitumor activity.

Primary Outcome Measure

Tulmimetostat Monotherapy Phase 1: Frequency of Dose-limiting toxicities (DLTs) [ Time Frame: DLTs assessed during Cycle 1 (cycle = 28 days) ]

Central Contacts

Locations (22)

FacilityCityStateZIPSite coordinators
H. Lee Moffitt Cancer Center and Research InstituteTampaFlorida33612-
Emory University School of MedicineAtlantaGeorgia30322
Jennifer Scalici, MD (PRINCIPAL_INVESTIGATOR)
University of ChicagoChicagoIllinois60637
Hedy L Kindler, MD (PRINCIPAL_INVESTIGATOR)
Loyola University Medical CenterMaywoodIllinois60153-
University of Maryland Medical CtrBaltimoreMaryland21201-
Dana Farber Cancer Institute (HARVARD)BostonMassachusetts02215-
Massachusetts General Hospital (MGH)BostonMassachusetts02114
Ryan Sullivan, MD (PRINCIPAL_INVESTIGATOR)
University of Michigan Rogel Cancer CenterAnn ArborMichigan48109-
Hackensack University Medical CenterHackensackNew Jersey07601-
Roswell Park Cancer InstituteBuffaloNew York14203-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
NYU Langone Medical CenterNew YorkNew York10016-
Weill Medical College of Cornell UniversityNew YorkNew York10021-
University of Rochester Medical CenterRochesterNew York14642-
Montefiore Einstein Center for Cancer Care (MECCC)The BronxNew York10467-2490-
University of Cincinnati Cancer InstituteCincinnatiOhio45219-
Abramson Cancer Center of the University of PennsylvaniaPhiladelphiaPennsylvania19104
Lainie Martin, MD (PRINCIPAL_INVESTIGATOR)
South Texas Accelerated Research Therapeutics (START) - Midwest LocationSan AntonioTexas78922-
South Texas Accelerated Research Therapeutics (START) - San AntonioSan AntonioTexas78229-
University of Virginia Health System (UVAHS)CharlottesvilleVirginia22908
Linda Duska, MD (PRINCIPAL_INVESTIGATOR)
Fred Hutchinson Cancer CenterSeattleWashington98109
Kalyan Banda, MD (PRINCIPAL_INVESTIGATOR)
Swedish Cancer InstituteSeattleWashington98104
Charles Drescher, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Tampa, FL

By condition
Endometrial cancerProstate cancer
By specialty
OncologyGynecologic oncologyWomen's healthProstate oncologyMen's healthUrology
By research site
H. Lee Moffitt Cancer Center and Research Institute· Tampa, FLEmory University School of Medicine· Atlanta, GAUniversity of Chicago· Chicago, ILLoyola University Medical Center· Maywood, ILUniversity of Maryland Medical Ctr· Baltimore, MDDana Farber Cancer Institute (HARVARD)· Boston, MA

Related Studies